Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Outcomes and Treatment Sequences of Therapies with BCL2- and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Doerfel, Joerg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al-Sawaf, Petra Langerbeins, Paula Cramer, Barbara F. Eichhorst, Michael Hallek, Kirsten Fischer, Anna Maria Fink

Blood (2023) 142 (Supplement 1): 4644.

https://doi.org/10.1182/blood-2023-185741

Published: 2023

Journal Articles

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Blood (2016) 128 (22): 229.

https://doi.org/10.1182/blood.V128.22.229.229

Published: 2016

Journal Articles

How to Treat Chronic Lymphocytic Leukemia? Data From a Clinical Registry by Office-Based Hematologists in Germany (TLN Registry)

Wolfgang Knauf, MD, Wolfgang Abenhardt, MD, Ali Aldaoud, MD, Christian Lerchenmüller, MD, Michaela Koska, Norbert Marschner, MD

Blood (2011) 118 (21): 4606.

https://doi.org/10.1182/blood.V118.21.4606.4606

Published: 2011

Journal Articles

Bendamustine Induces Higher Remission Rates, Prolongs Progression Free Survival as Well as Time to Next Treatment, and Improves Overall Survival for Patients In Complete Remission without Compromising Quality of Life When Compared to Chlorambucil In First Line Treatment of Chronic Lymphocytic Leukemia

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Marina Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Françoise Huguet, MD, Ilaria Del Guidice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo

Blood (2010) 116 (21): 2449.

https://doi.org/10.1182/blood.V116.21.2449.2449

Published: 2010

Journal Articles

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Wolfgang Ulrich Knauf, MD, Toshko Lissitchkov, MD, Ali Aldaoud, MD, Anna Liberati, MD, Javier Loscertales, MD, Raoul Herbrecht, MD, Gunnar Juliusson, MD, Gerhard Postner, MD, Liana Gercheva, MD, Stefan Goranov, MD, Martin Becker, MD, Hans-Joerg Fricke, MD, Francoise Huguet, MD, Ilaria Del Giudice, MD, Peter Klein, Karlheinz Merkle, MD, Marco Montillo, MD

Blood (2009) 114 (22): 2367.

https://doi.org/10.1182/blood.V114.22.2367.2367

Published: 2009

Journal Articles

Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study.

Wolfgang Ulrich Knauf, Toshko Lissitchkov, Ali Aldaoud, Anna Liberati, Javier Loscertales, Roul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, Liana Gercheva, Stefan Goranov, MD, Martin Becker, Klaus Hoeffken, Francoise Huguet, Robert Foa, MD, Karlheinz Merkle, Marco Montillo

Blood (2008) 112 (11): 2091.

https://doi.org/10.1182/blood.V112.11.2091.2091

Published: 2008

Journal Articles

The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial

Eva Hoster, Michael Unterhalt, PhD, Bernhard Wörmann, Ulrich Dührsen, Bernd Metzner, Hartmut Eimermacher, Andreas Neubauer, Hannes Wandt, Hjalmar Steinhauer, Sonja Martin, Else Heidemann, Ali Aldaoud, Wolfgang Hiddemann, Martin Dreyling

Blood (2008) 112 (11): 3049.

https://doi.org/10.1182/blood.V112.11.3049.3049

Published: 2008

Journal Articles

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Blood (2008) 112 (11): 2599.

https://doi.org/10.1182/blood.V112.11.2599.2599

Published: 2008

Journal Articles

Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.

Wolfgang Ulrich Knauf, MD, Toshko Lissichkov, M.D., Ali Aldaoud, M.D., Raoul Herbrecht, M.D., Anna Marina Liberati, M.D., Javier Loscertales, M.D., Gunnar Juliusson, M.D., Christian Dittrich, M.D., Karlheinz Merkle, M.D.

Blood (2007) 110 (11): 2043.

https://doi.org/10.1182/blood.V110.11.2043.2043

Published: 2007

Journal Articles

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Rudolf Weide, MD, Georg Hess, MD, Hubert Koeppler, MD, Jochen Heymanns, MD, Joerg Thomalla, MD, Ali Aldaoud, MD, Christoph Losem, MD, Stefan Schmitz, MD, Ursula Haak, MD, Christoph Huber, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, Martin Dreyling, MD

Blood (2006) 108 (11): 2480.

https://doi.org/10.1182/blood.V108.11.2480.2480

Published: 2006

Journal Articles

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Blood (2005) 106 (12): 3725–3732.

https://doi.org/10.1182/blood-2005-01-0016

Published: 2005

Journal Articles

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

Martin Dreyling, Georg Lenz, Eva Hoster, Achiel Van Hoof, Christian Gisselbrecht, Rudolf Schmits, Bernd Metzner, Lorenz Truemper, Marcel Reiser, Hjalmar Steinhauer, Jean-Michel Boiron, Marc A. Boogaerts, Ali Aldaoud, Vittorio Silingardi, Hanneke C. Kluin-Nelemans, Joerg Hasford, Reza Parwaresch, Michael Unterhalt, Wolfgang Hiddemann

Blood (2005) 105 (7): 2677–2684.

https://doi.org/10.1182/blood-2004-10-3883

Published: 2005

Journal Articles

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, MD, PhD, Roswitha Forstpointner, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, PhD, Rudolf Schmits, MD, PhD, Bernd Metzner, MD, Marcel Reiser, MD, Eva Lengfelder, MD, PhD, Bernhard Woermann, MD, PhD, Hariett Harder, MD, Susanna Hegewisch-Becker, MD, PhD, Wolfgang Berdel, MD, PhD, Georg Hess, MD, Hartmut Eimermacher, MD, Ali Aldaoud, MD, Manfred Planker, MD, Reza Parwaresch, MD, PhD, Martin Dreyling, MD, PhD, Michael Unterhalt, MD

Blood (2004) 104 (11): 161.

https://doi.org/10.1182/blood.V104.11.161.161

Published: 2004

Journal Articles

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free Survival in Mantle Cell Lymphoma - Long Term Follow up of a Prospective Randomized Trial of the European MCL Network .

Martin H. Dreyling, MD, PhD, Georg Lenz, MD, Eva Schiegnitz, MSc, Achiel van Hoof, MD, Christian Gisselbrecht, MD, PhD, Michael Pfreundschuh, MD, PhD, Bernd Metzner, MD, Lorenz H. Truemper, MD, PhD, Marcel Reiser, MD, Hjalmar B. Steinhauer, MD, PhD, Jean-Michel Boiron, MD, PhD, Marc A. Boogaerts, MD, PhD, Ali Aldaoud, MD, Vittorio Silingardi, MD, PhD, Hanneke C. Kluin-Nelemans, MD, PhD, Joerg Hasford, MD, PhD, Reza Parwaresch, MD, PhD, Unterhalt Michael, MD, PhD, Hiddemann Wolfgang, MD, PhD

Blood (2004) 104 (11): 7.

https://doi.org/10.1182/blood.V104.11.7.7

Published: 2004

Journal Articles

Bendamustine Versus Chlorambucil in Treatment-Naive B-CLL Patients.

Wolfgang Ulrich Knauf, M.D., Toshko Lissitchkov, M.D., Raoul Herbrecht, M.D., Javier Loscertales, M.D., Ali Aldaoud, M.D., Karlheinz Merkle, M.D.

Blood (2004) 104 (11): 4817.

https://doi.org/10.1182/blood.V104.11.4817.4817

Published: 2004

Journal Articles

Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective and Well Tolerated Immuno-Chemotherapy for Relapsed and Refractory Indolent Lymphomas - Results of a Multicentre Phase-II-Study of the German Low Grade Lymphoma Study Group ( GLSG ).

Rudolf Weide, Hubert Koeppler, Jochen Heymanns, Joerg Thomalla, Georg Hess, Heinhold Gamm, Ali Aldaoud, Stephan Schmitz, Ursula Haak, Dirk Plewe, Oswald Burkhard, Bernd Gaede, Fokke Hinrichs, Karl-Heinz Pflueger, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann

Blood (2004) 104 (11): 2482.

https://doi.org/10.1182/blood.V104.11.2482.2482

Published: 2004

NARROW

Outcomes and Treatment Sequences of Therapies with BCL2- and BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL): An Analysis of Patient Data within the German CLL Study Group (GCLLSG) Registry

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

How to Treat Chronic Lymphocytic Leukemia? Data From a Clinical Registry by Office-Based Hematologists in Germany (TLN Registry)

Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.

Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study.

The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Results of an International Phase III Study.

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free Survival in Mantle Cell Lymphoma - Long Term Follow up of a Prospective Randomized Trial of the European MCL Network .

Bendamustine Versus Chlorambucil in Treatment-Naive B-CLL Patients.

Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective and Well Tolerated Immuno-Chemotherapy for Relapsed and Refractory Indolent Lymphomas - Results of a Multicentre Phase-II-Study of the German Low Grade Lymphoma Study Group ( GLSG ).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only